Elucidating the specific pharmacological mechanism of motion (MOA) of naturally happening compounds can be tough. Whilst Tarselli et al. (sixty) made the very first de novo synthetic pathway to conolidine and showcased that this naturally developing compound correctly suppresses responses to equally chemically induced and inflammation-derived pain,